ReviewOncoTargets and therapy2021
Testing for
Review in OncoTargets and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- Critical Questions in Genomic Diagnostics for Veterinary Oncology: What We Need to Know.Veterinary and comparative oncology · 2026Review
- Machine Learning-Based Identification of Biomarkers for Early-Stage Non-Small Cell Lung Cancer Through Gene Expression Analysis.International journal of molecular sciences · 2026Article
- RORγ drives non-small cell lung cancer progression by upregulating the NGF signaling.Respiratory research · 2026Article
- Real-World Prevalence, Treatment Patterns, and Economic Impact of EGFR- and ALK-Targeted Therapies in Non-Small Cell Lung Cancer: A Nationwide Analysis from Greece.Current oncology (Toronto, Ont.) · 2025Article
- Evaluation of implementation of evolving practice patterns in the first-line treatment of patients with metastatic non-small cell lung cancer in Turkiye (ESTIMATE): a national, multicenter, retrospective, real-world evidence study.Future oncology (London, England) · 2025Article
- City scale related to epidermal growth factor receptor mutations status in Chinese non-small cell lung cancer.Discover oncology · 2025Article
- Survival Nomogram for Lung Adenocarcinoma Patients With Bone Metastasis Based on the SEER Database and an External Validation Cohort.Cancer reports (Hoboken, N.J.) · 2025Article
- Targeting EGFR-TKI resistance in lung cancer: Role of miR-5193/miR-149-5p loaded NK-EVs and Carboplatin combination.International journal of pharmaceutics · 2025Article
- Advancements in pathology: Digital transformation, precision medicine, and beyond.Journal of pathology informatics · 2025Review
- Article
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions.Journal of clinical medicine · 2024Review
- Biomarker Testing Journey Among Patients with Advanced Solid Tumors and Treatment Patterns by Homologous Recombination Repair Status: A Clinico-Genomic Database Study.Advances in therapy · 2024Article
- Addressing the unmet need in NSCLC progression with advances in second-line therapeutics.Exploration of targeted anti-tumor therapy · 2024Review
- Plasma-Based Comprehensive Genomic Profiling DNA Assays for Non-Small Cell Lung Cancer: A Health Technology Assessment.Ontario health technology assessment series · 2024Article
- A narrative review of methods for the identification ofTranslational lung cancer research · 2023Review
- Cancer-Testis Antigen LDH-C4 in Tissue, Serum, and Serum-Derived Exosomes Serves as a Promising Biomarker in Lung Adenocarcinoma.Frontiers in oncology · 2022Article
- The NGS and PCR-based Detection of EGFR Mutations in Liquid Biopsy: A Systematic Review and Meta-analysis Compared With Tissue Biopsy in Treatment-naïve Patients With Non-small Cell Lung Cancer.Cancer diagnosis & prognosisReview
- The Role of Programmed Cell Death Receptor 1 in Lung Cancer.In vivo (Athens, Greece)Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 9 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment of patients with advanced non-small-cell lung cancer (NSCLC) in recent years has been increasingly guided by biomarker testing. Testing has centered on driver genetic alterations involving the epidermal growth factor receptor (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.